Navigation Links
Lorus Therapeutics Receives $600 Thousand From Escrow Account
Date:7/16/2008

TORONTO, July 16 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (TSX: LOR, AMEX: LRP) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced that the Corporation has received the $600 thousand originally held in escrow in connection with Lorus' corporate reorganization completed on July 10, 2007. The Corporation has received total net proceeds of $6.9 million in non-dilutive financing as part of this transaction.

For further information about the corporate reorganization, please refer to our press release dated July 10, 2007 available on Lorus' website or at Sedar.com.

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to: our research program plans, our plans to conduct clinical trials, the successful and timely completion of clinical studies and the regulatory approval process, our ability to fund future research, our plans to obtain partners to assist in the further development of our product candidates, the establishment of corporate alliances, the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "believe", "plan", "expect", "intend", "will", "should", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achi
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
7. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
8. Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
11. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Mass. , April 16, 2015  In recognition of ... collaborated with hemophilia advocacy groups to illuminate more than 15 ... , including Boston,s Zakim Bridge and ... New Orleans, Mercedes-Benz Superdome and ... occur during the evening of April 17, and coincide with ...
(Date:4/16/2015)... /CNW/ - Bioenterprise Corporation is pleased to announce that it ... Charlottetown , PEI.  Bioenterprise has established a 3-year ... for the commercialization of agricultural technologies and innovations. ... ADAPT.  They have been at the heart of agri-innovation ... Dave Smardon , President & CEO of Bioenterprise ...
(Date:4/16/2015)... April 16, 2015  AnaptysBio, Inc., a leader ... antibodies, today announced the advancement of its ... IND-enabling studies. The Company,s anti-IL-36R therapeutic antibody, ... generalized pustular psoriasis (GPP), an orphan systemic ... is wholly owned within AnaptysBio,s proprietary antibody ...
(Date:4/16/2015)... , April 16, 2015  EMD Serono today ... Darmstadt, Germany , appointed ... Head of Global Clinical Development.  Dr. Reicin brings ... experience in Oncology and Immunology. She is an ... served as a Vice President in various capacities ...
Breaking Biology Technology:Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4Bioenterprise Corporation Expands into the Maritimes 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3
... the only one completely confused by the Cingular merger with ... facts of the deal. Cingular Wireless acquires the assets and ... have 46 million customers, topping now No. 2 carrier Verizon ... keeps the rights to the AT&T Wireless brand and plans ...
... of the statewide Wisconsin business-plan contest this year ... survive the first round than they did during the inaugural ... initial abstracts of business ideas has passed, a panel of ... The survivors, who must write extended summaries for a further ...
... of Wisconsin-Milwaukee The director of the university's ... would leave for the University of Cincinnati in April. Professor ... feel valued, and that UW-Milwaukee does not have good ... , Menasha, Wis. Banta Corporation said it would ...
Cached Biology Technology:Cingular confusion 2Cingular confusion 3Coaching available for business-plan contest survivors 2
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
(Date:4/10/2015)... DUBLIN , April 10, 2015 ... the addition of the "Security Competitive Profiles - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to ... solutions to the market, with a company focus on ... solution anticipated. Winning opportunities in the ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... - The idea is to teach the immune system of ... attack the insulin-producing cells of the pancreas. "We want ... who directs the Medical College of Georgia Immunotherapy Center. Type ... immune system targets healthy islet cells for destruction, leaving young ...
... , CAREFREE, A.Z. - Data from the ELLA ... time at the American Association for Cancer Research Conference on ... "Hispanics are the fastest-growing minority group in the United ... cancer," said Elena Martinez, Ph.D., professor of epidemiology at The ...
... a 60-million-year-old South American snake whose length and weight ... bit cuter and more cuddly. Named Titanoboa ... snake,s vertebrae suggest it weighed 1,140 kilograms (2,500 pounds) ... tip -- and that,s a conservative estimate. A report ...
Cached Biology News:Molecule that suppresses immune response under study in type 1 diabetes 2Molecule that suppresses immune response under study in type 1 diabetes 3Hispanic women and breast cancer: An understudied group 2Hispanic women and breast cancer: An understudied group 3Hispanic women and breast cancer: An understudied group 4At 2,500 pounds and 43 feet, prehistoric snake is the largest on record 2At 2,500 pounds and 43 feet, prehistoric snake is the largest on record 3
... Detergent Clean-up Micro Kit provides a fast and ... Triton X-100 and other detergents from small samples ... Norgens patented protein resin as an ion exchanger. ... g of either acidic or basic protein.A complete ...
Compound(s) screened through any number of client selected assays. Client also selects number of concentrations and replicates....
... cells form from a hematopoietic stem cells ... to the bone surface and lowering the ... around 4.5. The bone mineral is then ... and function is controlled primarily by Macrophage ...
Values of steady state parameters for enzyme activities are determined....
Biology Products: